Ly Tu

List of Publications by Citations

64 papers	3,355 citations	29 h-index	57 g-index
79 ext. papers	4,106 ext. citations	8.3 avg, IF	5 L-index

#	Paper	IF	Citations
64	Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 780-9	10.2	244
63	Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. *Respiratory Research*, **2009**, 10, 6	7.3	210
62	Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 1041-7	10.2	173
61	Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. *Circulation Research*, **2006**, 98, 1323-30	15.7	158
60	Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. *Journal of Clinical Investigation*, **2009**, 119, 512-23	15.9	148
59	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. *Journal of Clinical Investigation*, **2016**, 126, 3207-18	15.9	144
58	RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 1151-8	10.2	134
57	Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. *Circulation*, **2014**, 129, 1586-97	16.7	131
56	Pathogenesis of pulmonary arterial hypertension: lessons from cancer. *European Respiratory Review* , **2013**, 22, 543-51	9.8	126
55	Role for interleukin-6 in COPD-related pulmonary hypertension. *Chest*, **2009**, 136, 678-687	5.3	126
54	Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. *Circulation*, **2014**, 129, 1332-40	16.7	110
53	New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. *Chest*, **2015**, 147, 529-537	5.3	109
52	Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 983-97	10.2	108
51	Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 45, 311-22	5.7	98
50	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. *Journal of Clinical Investigation*, **2018**, 128, 1956-1970	15.9	87
49	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. *European Respiratory Journal*, **2012**, 40, 895-904	13.6	84
48	A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 666-76	10.2	68

47	Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter. *FASEB Journal*, **2009**, 23, 4135-47	0.9	66
46	Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. *European Respiratory Journal*, **2009**, 34, 1100-10	13.6	61
45	Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 193, 1410-20	10.2	60
44	Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. *Circulation*, **2018**, 137, 910-924	16.7	60
43	Leptin signalling system as a target for pulmonary arterial hypertension therapy. *European Respiratory Journal*, **2015**, 45, 1066-80	13.6	48
42	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. *Circulation Research*, **2019**, 124, 846-855	15.7	48
41	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. *Annals of the Rheumatic Diseases*, **2017**, 76, 1931-1940	2.4	47
40	Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. *Cardiovascular Research*, **2020**, 116, 885-893	9.9	35
39	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. *Respiratory Research*, **2014**, 15, 65	7.3	34
38	Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. *Chest*, **2016**, 149, 1482-93	5.3	33
37	Dasatinib increases endothelial permeability leading to pleural effusion. *European Respiratory Journal*, **2018**, 51,	13.6	29
36	T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. *Arthritis Research and Therapy*, **2018**, 20, 197	5.7	29
35	Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 766-782	9.4	27
34	Renal Denervation Reduces Pulmonary Vascular Remodeling and Right Ventricular Diastolic Stiffness in Experimental Pulmonary Hypertension. *JACC Basic To Translational Science*, **2017**, 2, 22-35	8.7	26
33	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. *Cardiovascular Research*, **2020**, 116, 686-697	9.9	25
32	Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension. *Cardiovascular Research*, **2019**, 115, 432-439	9.9	24
31	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. *European Respiratory Journal*, **2019**, 54,	13.6	20
30	Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. *Journal of Thoracic and Cardiovascular Surgery*, **2009**, 137, 1538-46	1.5	20

29	Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 342-55	10.2	16
28	Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. *Journal of Medicinal Chemistry*, **2018**, 61, 2725-2736	8.3	14
27	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. *Arthritis and Rheumatology*, **2017**, 69, 2209-2221	9.5	14
26	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. *FASEB Journal*, **2019**, 33, 3670-3679	0.9	14
25	The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient. *Cells*, **2020**, 9,	7.9	13
24	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	12
23	Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension. *Frontiers in Physiology*, **2018**, 9, 555	4.6	11
22	Right lung ischemia induces contralateral pulmonary vasculopathy in an animal model. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 143, 967-73	1.5	11
21	New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways. *Current Opinion in Pulmonary Medicine*, **2017**, 23, 377-385	3	11
20	Angiomatoid fibrous histiocytoma of the pulmonary artery: a multidisciplinary discussion. *Histopathology*, **2014**, 65, 278-82	7.3	9
19	Pulmonary hemodynamic responses to inhaled NO in chronic heart failure depend on PDE5 G(-1142)T polymorphism. *Pulmonary Circulation*, **2011**, 1, 377-82	2.7	9
18	Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease. *European Respiratory Journal*, **2020**, 55,	13.6	9
17	An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. *Nature Communications*, **2021**, 12, 1720	17.4	9
16	Altered TGF/SMAD Signaling in Human and Rat Models of Pulmonary Hypertension: An Old Target Needs Attention. *Cells*, **2021**, 10,	7.9	9
15	A genome-wide association analysis identifies | locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population. *Oncotarget*, **2017**, 8, 74917-74926	3.3	7
14	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. *Cardiovascular Research*, **2021**,	9.9	7
13	The Thousand Faces of Leptin in the Lung. *Chest*, **2021**, 159, 239-248	5.3	7
12	Purinergic Dysfunction in Pulmonary Arterial Hypertension. *Journal of the American Heart Association*, **2020**, 9, e017404	6	6

List of Publications

11	Therapeutic potential of melatonin and melatonergic drugs on K18-hACE2 mice infected with SARS-CoV-2. *Journal of Pineal Research*, **2021**, e12772	10.4	6
10	Serum and pulmonary uric acid in pulmonary arterial hypertension. *European Respiratory Journal*, **2021**, 58,	13.6	6
9	Emerging Molecular Targets for Anti-proliferative Strategies in Pulmonary Arterial Hypertension. *Handbook of Experimental Pharmacology*, **2013**, 409-436	3.2	5
8	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. *Cardiovascular Research*, **2021**, 117, 1391-1401	9.9	5
7	Emerging molecular targets for anti-proliferative strategies in pulmonary arterial hypertension. *Handbook of Experimental Pharmacology*, **2013**, 218, 409-36	3.2	4
6	Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension: Implications for Therapy. *Chest*, **2021**,	5.3	4
5	Lower Plasma Melatonin Levels Predict Worse Long-Term Survival in Pulmonary Arterial Hypertension. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
4	Response by Guignabert et al to Letter Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension". *Circulation Research*, **2019**, 124, e82-e83	15.7	2
3	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.. *Arthritis Research and Therapy*, **2022**, 24, 13	5.7	1
2	Platelet-Derived Growth Factor Receptor Type Activation Drives Pulmonary Vascular Remodeling Via Progenitor Cell Proliferation and Induces Pulmonary Hypertension.. *Journal of the American Heart Association*, **2022**, e023021	6	1
1	Pulmonary hypertension associated with neurofibromatosis type 2. *Pulmonary Circulation*, **2021**, 11, 20458940211029550	2.7	0